TAAT hemp cigarettes' unsubstantiated cessation and harm reduction claims

Area of Science:

• Tobacco regulatory science
• Hemp product marketing analysis
• Consumer health claims investigation

Background:

• The US Food and Drug Administration (FDA) regulates tobacco product harm reduction claims.
• Hemp products with less than 0.3% delta-9-tetrahydrocannabinol (THC) are not federally regulated as controlled substances.
• Hemp cigarettes may bypass tobacco and drug regulations, posing potential health risks.

Purpose of the Study:

• To analyze marketing claims on TAAT's consumer website.
• To determine if TAAT made unsubstantiated harm reduction or therapeutic claims.
• To assess potential regulatory actions by the FDA and FTC.

Main Methods:

• Analysis of TAAT's consumer website in August-September 2024.
• Identification and categorization of harm reduction and therapeutic claims.
• Assessment of claim substantiation and regulatory compliance.

Main Results:

• 36.1% of sentences on TAAT's website contained harm reduction or therapeutic claims.
• Most frequent claims related to cessation, no nicotine, no tobacco, and hemp content.
• The website lacked independent verification for the presented claims.

Conclusions:

• TAAT's website features numerous unsubstantiated health claims.
• The FDA can act against unauthorized therapeutic claims for unapproved products.
• Federal and state agencies can address deceptive marketing of hemp cigarettes.